Revenue - Additional Information (Detail)	3 Months Ended	9 Months Ended
	Mar. 31, 2020 USD ($) $ / shares	Mar. 31, 2020 USD ($) $ / shares
Disaggregation Of Revenue [Line Items]
Revenue, practical expedient, remaining performance obligation, description		In accordance with ASU 2014-09, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of Company’s performance to date. However, the Company periodically enters into arrangements with customers to provide diagnostic testing and/or pharmaceutical and clinical services that may have terms longer than one year and include multiple performance obligations.
Revenue, practical expedient, remaining performance obligation		true
Revenue, practical expedient, initial application and transition, nondisclosure of transaction price allocation to remaining performance obligation		true
Revenue, remaining performance obligation	$ 4,100,000	$ 4,100,000
Capitalized costs incurred to obtain or fulfill contract	0	$ 0
Revenue practical expedient, incremental cost of obtaining contract		true
Revenue, performance obligation, description of payment terms		This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payments terms have a payback period of less than one year.
Revenue increase (decrease) performance obligation	$ (5,500,000)	$ (10,800,000)
Earnings per share increase (decrease) performance obligation | $ / shares	$ (0.06)	$ (0.11)